K
KalVista Pharmaceuticals, Inc. (KALV)
NGM – Real vaqt narxi. Valyuta: USD
26.73
+0.02 (0.07%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
26.73
+0.02 (0.07%)
Yopilishda: May 12, 2026, 4:00 PM EDT
KalVista Pharmaceuticals, Inc., biofarmatsevtika kompaniyasi, noyob kasalliklarga chalingan va davolashga muhtoj bemorlar uchun og'iz orqali yuboriladigan dorilarni ishlab chiqadi. Uning yetakchi mahsuloti nomzodi EKTERLY bo'lib, bu irsiy angionevrotik shish (IAO) ning o'tkir hujumlarini davolash uchun plazma kallikreinining tez ta'sir qiluvchi kuchli ingibitoridir. Kompaniya shuningdek, og'izda eruvchi tabletka shaklini; IAO bo'lgan bolalar uchun KONFIDENT-KID; va o'smirlar va kattalar bemorlarda sebetralstat va ODT shaklini baholash uchun KONFIDENT va KONFIDENT-S ni ishlab chiqmoqda. KalVista Pharmaceuticals, Inc. kompaniyasining shtab-kvartirasi Framingham, Massachusets shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christopher L. Hamblett Ph.D. | Senior Vice President of Corporate Development |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Mr. Benjamin L. Palleiko | CEO & Director |
| Mr. Bilal Arif | Chief Operating Officer |
| Mr. Brian Krex J.D. | General Counsel |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 10-KT/A | d121999d10kta.htm |
| 2026-04-29 | SC14D9C | ef20071871_sc14d9c.htm |
| 2026-04-29 | 8-K | ef20071670_8k.htm |
| 2026-03-25 | 10-KT | kalv-20251231.htm |
| 2026-01-26 | S-8 | d63436ds8.htm |
| 2026-01-08 | 8-K | d11988d8k.htm |
| 2025-11-10 | 10-Q | kalv-20250930.htm |
| 2025-10-06 | 8-K | d42627d8k.htm |
| 2025-10-02 | 8-K | d945945d8k.htm |
| 2025-09-29 | 8-K | d83242d8k.htm |
| Mr. Brian Piekos | Chief Financial Officer |
| Mr. Ryan Baker | Head of Investor Relations |
| Ms. Linea Aspesi | Chief People Officer |
| Ms. Rachel M. Morten | Senior Vice President of Regulatory Affairs & QA |